News
Join CILcare and CBSET for a Continuing Education Course on Ototoxicity
We are pleased to announce that CBSET and CILcare will be hosting a Continuing Education session entitled "Best Practices for Successfully Assessing Ototoxicity in Drug Development" on Sunday, March 27th, at 1:15 PM (PST). Hearing loss is a major global health issue...
Best practices for the conduct of preclinical ototoxicity evaluation : Talking Tox Webinar Replay
CILcare is pleased to share the replay of the Talking Tox Webinar that took place as part of ACT's 42nd virtual annual meeting, featuring experts from the FDA, CILcare and CBSET Ototoxicity resulting in inner ear damage is a leading cause of acquired hearing loss...
CILcare publishes new data on noise-induced hidden hearing loss
We are excited to announce that CILcare has released a new publication entitled, "Impulse Noise Induced Hidden Hearing Loss, Hair Cell Ciliary Changes and Oxidative Stress in Mice", in the journal Antioxidants, special issue "Oxidative Stress and Inflammation in...
CILcare will be presenting a workshop with its partner CBSET at the ARO 2022 meeting
We are pleased to announce that CILcare and its partner CBSET are organizing a workshop that will gather renowned experts in the field of inner ear diseases. Recent advances in understanding the mechanisms involved in inner ear diseases have accelerated the...
Upcoming webinar on ototoxicity – 20 January 2022: save the date!
CILcare is pleased to announce that our Global Head of R&D Operations Management, Aurore Marie, will present the latest advances on ototoxicity during the CBSET Talking Tox Webinar as part of ACT's 42nd virtual annual meeting. We are also thrilled to announce the...
CILcare acquires ISO 9001:2015 certification, demonstrating its commitment to quality and customer excellence
Montpellier, November 8th, 2021: CILcare, the world leading CRO specialized in hearing disorders, is proud to announce it has been awarded the ISO 9001:2015 certification for its quality management system that includes the conduct of pharmacokinetics, efficacy,...
Aurore Marie promoted as Global Head, R&D Operations Management, and CILcare’s Board Member
Montpellier, October 13th, 2021: CILcare, the world leading CRO specialized in ear disorders, is pleased of nominating Aurore Marie at the position of Global Head, R&D Operations Management. In her new role, Aurore Marie will drive the support to production...
CILcare will present a valuable diagnostic tool to assess the tolerance of otic products in pets at the 32nd ESVD Congress
CILcare’s team is pleased to announce that the abstract co-written with Virbac, a top 10 animal health company, entitled “Ear inflammation and hearing measurements: taking advantage of preclinical tools to assess the Tolerance of otic products“ has been accepted for...
